18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies - 16/06/22
Doi : 10.1016/j.cpet.2022.03.007
Gopinath Gnanasegaran, MSc, MD, FRCP a, ⁎ 
, Kanhaiyalal Agrawal, MD b, Simon Wan, FRCR c
, Kanhaiyalal Agrawal, MD b, Simon Wan, FRCR c a Royal Free NHS Foundation Trust, London, United Kingdom
b All India Institute of Medical Sciences, Bhubaneswar, India
c University College London Hospitals NHS Foundation Trust, London, United Kingdom
∗Corresponding author.
Résumé |
Molecular imaging with PET-computerized tomography (PET-CT) plays an important role in oncology. There is current and evolving evidence supporting the use of fluorodeoxyglucose (FDG) and non-FDG tracers in assessment patients with hepatobiliary and pancreatic cancers in various clinical scenarios. In this chapter, we discuss the advantages and limitations of FDG and non-FDG PET-CT in the management of patients with hepatobiliary and pancreatic cancers.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatocellular cancer, Gall bladder cancer, Pancreatic cancer, Cholangiocarcinoma
Plan
© 2022
Elsevier Inc. Tous droits réservés.
Vol 17 - N° 3
P. 369-388 - juillet 2022 Retour au numéro
Article précédent
- An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non–Thyroid Endocrine Neoplasms
- Aadil Adnan, Shobhana Raju, Rakesh Kumar, Sandip Basu
- Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer
- Hossein Jadvar, Patrick M. Colletti
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?